2025 年指導
葛蘭素史克提供了固定匯率 (CER) 下的全年指導。
- 預計營業額增長3％至5％
- 預計核心營業利潤增長6％至8％
- 預計核心每股收益增長6％至8％
此指導的支持來自以下2025年全年固定匯率 (CER) 下的營業額預期：
- 專業藥品：預計營業額將低雙位數百分比增長
- 疫苗：預計營業額將低單位數百分比下降
- 普通藥品：預計營業額基本保持穩定
以上內容來自Benzinga Earnings專欄，原文如下：
2025 Guidance
GSK provides its full-year guidance at constant exchange rates (CER).
- Turnover is expected to increase between 3 to 5 per cent
- Core operating profit is expected to increase between 6 to 8 per cent
- Core earnings per share is expected to increase between 6 to 8 per cent
This guidance is supported by the following turnover expectations for full-year 2025 at CER
- Specialty Medicines – expected increase of a low double-digit per cent in turnover
- Vaccines – expected decrease of a low single-digit per cent in turnover
- General Medicines – expected to be broadly stable for turnover
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。